Plus, news about First Wave BioPharma:
Monte Rosa’s $100M offering: The molecular glue degrader biotech priced the offering at $4.70 per share $GLUE and expects it to close on May 20. At the end of March, it had enough cash and equivalents to take the biotech into the first half of 2026. — Kyle LaHucik
Alexion drops Zealand Pharma’s complement drug: The Danish biotech said AstraZeneca’s rare disease unit stopped developing Zealand’s preclinical complement C3 inhibitor, ZP10068, for “business reasons.” Alexion plans to hand the program back to Zealand. — Ayisha Sharma
First Wave BioPharma rebrands: Expect to start referring to the Florida biotech as Entero Therapeutics starting Friday, when the company begins its new chapter as $ENTO. That said, the gastrointestinal diseases biotech shouldn’t be confused with Entera Bio or Entrada Therapeutics. — Kyle LaHucik